Our patents
Cantargia's strategy is to obtain an extensive patent protection for its current and future product candidates. Cantargia has patent protection for the treatment of a large number of different cancer forms using antibodies directed against IL1RAP. Cantargia also has a patent family covering the product candidates nadunolimab (CAN04) and CAN10, as well as several patent families covering other antibodies targeting IL1RAP. Cantargia's patent strategy is global, and covers markets deemed to be of clinical and commercial relevance for the product pipeline.
| Patent family | Patent application | Approved patents | Validity |
|---|---|---|---|
| CAN04 (Product) | Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, South Africa, South Korea, USA | Australia, China, Europe (Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Great Britain, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey), Israel, Japan, Mexico, Singapore, South Africa, USA | 2035 |
| Solid tumors (Treatment/Diagnosis) | Australia, Brazil, Canada, China, Europe, Japan, Mexico, South Korea, USA | Australia, Brazil, Canada, China, Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland), Japan, Mexico, South Korea, USA | 2032 |
| Hematological cancers (Treatment/Diagnosis) | Australia, Canada, China, Europe, Israel, Japan, Mexico, South Africa, USA | Australia, Canada, China, Europe (France, Germany, Great Britain, Italy, Netherlands, Spain, Switzerland), Israel, Japan, Mexico, South Africa, USA | 2030 |
| Leukemias (Treatment) | Europe, USA | Europe (France, Germany, UK), USA | 2029 |
| CAN10 (Product) | PCT, USA | USA | 2041 |
| CAN03 (Product) | China, Europe, Japan, USA | China, Europe (France, Germany, UK), Japan, USA | 2035 |
| Anti-IL1RAP antibodies (Product) | China, Europe, India, Japan, USA | Japan, USA | 2037 |
| Biepitopic antibody (Product) | China, Europe, Japan, USA | 2039 |
